' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8
USERS' SCORE
Good
Based on 1 Review
8.3
Supplement Facts
Serving Size: 31 g (About 1 Scoop)
Amount Per Serving
%DV
Calories
120
Total Fat
1.5 g
2%
Saturated Fat
1 g
5%
Cholesterol
60 mg
20%
Sodium
130 mg
6%
Total Carbohydrate
3 g
1%
Total Sugars
2 g
Protein
24 g
48%
Calcium
140 mg
10%
Potassium
150 mg
4%
Top Medical Research Studies
9
Ligelizumab effectively treats CSU
From wheal to wellness: efficacy and safety of ligelizumab in chronic spontaneous urticaria: a systematic review and meta-analysis.
Direct connection to protein treatment
We explored how ligelizumab, a humanized monoclonal antibody that targets IgE, can help those suffering from chronic spontaneous urticaria (CSU). This condition features persistent hives and itching lasting more than six weeks, often causing significant discomfort and distress.
To gain a clearer understanding, we reviewed various studies, focusing on randomized controlled trials comparing ligelizumab with a placebo. Our analysis included data from 2,581 patients and revealed that ligelizumab significantly improved symptoms. A crucial finding was that the 72 mg dose of ligelizumab effectively reduced itch severity and overall hives activity.
We observed that patients receiving this dosage experienced a marked improvement in their quality of life, as indicated by various scores measuring skin and itch severity. On the other hand, while 120 mg doses led to further enhancements, mild adverse effects were noted. Thankfully, no significant adverse effects were reported with the lower dose.
In summary, ligelizumab shows great promise as an effective treatment for CSU, significantly alleviating symptoms and enhancing patients' well-being when compared to placebo, albeit with some mild side effects at higher doses.
To gain a clearer understanding, we reviewed various studies, focusing on randomized controlled trials comparing ligelizumab with a placebo. Our analysis included data from 2,581 patients and revealed that ligelizumab significantly improved symptoms. A crucial finding was that the 72 mg dose of ligelizumab effectively reduced itch severity and overall hives activity.
We observed that patients receiving this dosage experienced a marked improvement in their quality of life, as indicated by various scores measuring skin and itch severity. On the other hand, while 120 mg doses led to further enhancements, mild adverse effects were noted. Thankfully, no significant adverse effects were reported with the lower dose.
In summary, ligelizumab shows great promise as an effective treatment for CSU, significantly alleviating symptoms and enhancing patients' well-being when compared to placebo, albeit with some mild side effects at higher doses.
Read More
8
Impact of omalizumab on hives
EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial.
Protein treatment's multifaceted effects
We investigated the effects of protein treatment, specifically omalizumab, in managing chronic spontaneous urticaria (hives) that does not respond to standard antihistamines. Omalizumab is a monoclonal antibody that targets IgE, a key player in allergic reactions. In this multicenter trial, we aimed to find out if patients who have stable disease control after receiving omalizumab every four weeks could remain well-managed with injections given every six weeks.
After 12 weeks on the standard treatment, participants who scored well on the Urticaria Control Test were randomly assigned to either continue the four-week schedule or switch to the extended six-week schedule. We tracked various health metrics and symptoms over 36 weeks to see how well the new regimen worked compared to the original.
The ultimate goal was to determine if this longer interval between treatments could maintain the same level of disease control, potentially benefiting patients by reducing treatment frequency and improving convenience. As we compile the results, we’re eager to share findings that could influence how chronic hives are treated moving forward.
After 12 weeks on the standard treatment, participants who scored well on the Urticaria Control Test were randomly assigned to either continue the four-week schedule or switch to the extended six-week schedule. We tracked various health metrics and symptoms over 36 weeks to see how well the new regimen worked compared to the original.
The ultimate goal was to determine if this longer interval between treatments could maintain the same level of disease control, potentially benefiting patients by reducing treatment frequency and improving convenience. As we compile the results, we’re eager to share findings that could influence how chronic hives are treated moving forward.
Read More
4
Potential aid against honey bee viruses
Gut-binding peptides as potential tools to reduce virus binding to honey bee gut surface proteins.
Examines peptide-virus interactions
We explored how certain proteins, known as gut-binding peptides, can impact honey bee health by interfering with virus interactions. Honey bees face many stressors, including bad mites and harmful viruses, which can lead to significant colony loss. Our study focused on two viruses that threaten bees, the Deformed Wing Virus (DWV) and the Israeli Acute Paralysis Virus (IAPV).
To identify effective peptides, we fed adult honey bees a library of peptides and found one named BBP2.1. This peptide helps reduce the ability of these viruses to bind to honey bee gut proteins, which is an important step in preventing viral infections. We conducted various tests, including pull-down assays and competition assays, to confirm that BBP2.1 could effectively bind in the honey bee gut.
While BBP2.1 was effective at reducing the movement of DWV within the bees, it did not significantly help with IAPV-related issues. Therefore, while this peptide shows promise for addressing DWV, it doesn’t seem to help with IAPV and its associated mortality. Overall, our findings indicate that gut-binding peptides can be potential tools for protecting honey bees from detrimental virus impacts, but further research is needed for practical application.
To identify effective peptides, we fed adult honey bees a library of peptides and found one named BBP2.1. This peptide helps reduce the ability of these viruses to bind to honey bee gut proteins, which is an important step in preventing viral infections. We conducted various tests, including pull-down assays and competition assays, to confirm that BBP2.1 could effectively bind in the honey bee gut.
While BBP2.1 was effective at reducing the movement of DWV within the bees, it did not significantly help with IAPV-related issues. Therefore, while this peptide shows promise for addressing DWV, it doesn’t seem to help with IAPV and its associated mortality. Overall, our findings indicate that gut-binding peptides can be potential tools for protecting honey bees from detrimental virus impacts, but further research is needed for practical application.
Read More
Most Useful Reviews
6
No allergic reactions
This is by far my favourite whey protein and the only one I can consume without severe allergies. The taste is just as described and does not resemble chalk! It’s delicious! I’ve tried vanilla ice cream and Double Rich Chocolate flavours, both are scrumptious. Previously, I’ve had life-threatening allergic reactions from other brands leading to hives and breathing difficulties, but this product has been fine for the last 3 months. I’ve included it in my daily smoothie, and it tastes delightful!
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8
9
CT-P39 shows similar performance
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.
Limited relevance to hives treatment
We explored the effectiveness of a new protein treatment called CT-P39, administered through an auto-injector, in comparison to an approved treatment known as omalizumab, delivered via a pre-filled syringe. This study aimed to understand whether these two methods have similar performance in healthy Japanese adults.
Participants were split into two groups, receiving either CT-P39 or omalizumab, both at a dose of 150 mg/mL. We focused on how well the body absorbed these treatments, measured by the area under the concentration-time curve and the maximum serum concentration. The results showed that the absorption rates for CT-P39 and omalizumab were comparable.
Along with the absorption rates, we also looked at various other factors like safety and any potential side effects. Most participants reported some adverse effects, but they were generally mild and not considered serious. Overall, while CT-P39 appears to function similarly to omalizumab, more research may be necessary to fully understand its specific impact on hives treatment.
Participants were split into two groups, receiving either CT-P39 or omalizumab, both at a dose of 150 mg/mL. We focused on how well the body absorbed these treatments, measured by the area under the concentration-time curve and the maximum serum concentration. The results showed that the absorption rates for CT-P39 and omalizumab were comparable.
Along with the absorption rates, we also looked at various other factors like safety and any potential side effects. Most participants reported some adverse effects, but they were generally mild and not considered serious. Overall, while CT-P39 appears to function similarly to omalizumab, more research may be necessary to fully understand its specific impact on hives treatment.
Read More
9
Ligelizumab effectively treats CSU
From wheal to wellness: efficacy and safety of ligelizumab in chronic spontaneous urticaria: a systematic review and meta-analysis.
Direct connection to protein treatment
We explored how ligelizumab, a humanized monoclonal antibody that targets IgE, can help those suffering from chronic spontaneous urticaria (CSU). This condition features persistent hives and itching lasting more than six weeks, often causing significant discomfort and distress.
To gain a clearer understanding, we reviewed various studies, focusing on randomized controlled trials comparing ligelizumab with a placebo. Our analysis included data from 2,581 patients and revealed that ligelizumab significantly improved symptoms. A crucial finding was that the 72 mg dose of ligelizumab effectively reduced itch severity and overall hives activity.
We observed that patients receiving this dosage experienced a marked improvement in their quality of life, as indicated by various scores measuring skin and itch severity. On the other hand, while 120 mg doses led to further enhancements, mild adverse effects were noted. Thankfully, no significant adverse effects were reported with the lower dose.
In summary, ligelizumab shows great promise as an effective treatment for CSU, significantly alleviating symptoms and enhancing patients' well-being when compared to placebo, albeit with some mild side effects at higher doses.
To gain a clearer understanding, we reviewed various studies, focusing on randomized controlled trials comparing ligelizumab with a placebo. Our analysis included data from 2,581 patients and revealed that ligelizumab significantly improved symptoms. A crucial finding was that the 72 mg dose of ligelizumab effectively reduced itch severity and overall hives activity.
We observed that patients receiving this dosage experienced a marked improvement in their quality of life, as indicated by various scores measuring skin and itch severity. On the other hand, while 120 mg doses led to further enhancements, mild adverse effects were noted. Thankfully, no significant adverse effects were reported with the lower dose.
In summary, ligelizumab shows great promise as an effective treatment for CSU, significantly alleviating symptoms and enhancing patients' well-being when compared to placebo, albeit with some mild side effects at higher doses.
Read More
9
Comparative study of HAE treatments
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.
Balanced comparison of treatments
In our investigation, we compared the effectiveness and safety of lanadelumab, a protein treatment, with approved long-term treatments for hereditary angioedema (HAE) in pediatric patients under 12 years old. We looked at studies to see how these treatments affected the frequency of hives, or attacks, in young patients.
Our research involved data from two key studies, one focusing on lanadelumab and the other on intravenous C1-esterase inhibitors (C1-INH). We found that lanadelumab, when administered every two weeks, significantly reduced the monthly attack rate of HAE. Specifically, it cut down attacks by over 82% compared to one dosage of C1-INH and nearly 89% compared to a lower dose.
In terms of safety, we noted that lanadelumab also lowered the risk of total adverse events by more than half when compared with C1-INH. These findings suggest that lanadelumab might be more effective and safer, leading to fewer side effects, which is a significant consideration for children dealing with HAE. However, it’s important to note that these findings stem from a small study sample, and larger trials would be essential to confirm these results and further explore how these treatments can protect young patients from painful hives.
Our research involved data from two key studies, one focusing on lanadelumab and the other on intravenous C1-esterase inhibitors (C1-INH). We found that lanadelumab, when administered every two weeks, significantly reduced the monthly attack rate of HAE. Specifically, it cut down attacks by over 82% compared to one dosage of C1-INH and nearly 89% compared to a lower dose.
In terms of safety, we noted that lanadelumab also lowered the risk of total adverse events by more than half when compared with C1-INH. These findings suggest that lanadelumab might be more effective and safer, leading to fewer side effects, which is a significant consideration for children dealing with HAE. However, it’s important to note that these findings stem from a small study sample, and larger trials would be essential to confirm these results and further explore how these treatments can protect young patients from painful hives.
Read More
9
Mizolastine and proteoglycan effective
Effects of combination of mizolastine and proteoglycan on chronic urticaria: a randomized controlled trial.
Calcium's isolated effect unclear
We set out to understand how a combination of mizolastine and proteoglycan affects chronic urticaria, a condition often marked by itchy hives. In our study, we divided participants into two groups: one receiving a combination treatment that included mizolastine and proteoglycan, while the other group was treated with a similar regimen minus proteoglycan.
Over the course of four weeks, those in the treatment group experienced a significant drop in their symptoms, with 44 out of 56 showing a decline of 60% or more on the symptoms decline index. Notably, this group also had a lower relapse rate over the following two months compared to the control group.
Although calcium gluconate was part of the treatment, we found it challenging to isolate its direct impact on the improvement of hives since other factors were at play in the combined treatment approach. Overall, the results suggest that while calcium was included in the regimen, it was the combination of mizolastine and proteoglycan that primarily led to the observed improvements.
Over the course of four weeks, those in the treatment group experienced a significant drop in their symptoms, with 44 out of 56 showing a decline of 60% or more on the symptoms decline index. Notably, this group also had a lower relapse rate over the following two months compared to the control group.
Although calcium gluconate was part of the treatment, we found it challenging to isolate its direct impact on the improvement of hives since other factors were at play in the combined treatment approach. Overall, the results suggest that while calcium was included in the regimen, it was the combination of mizolastine and proteoglycan that primarily led to the observed improvements.
Read More
9
Calcium's role in hives unclear
Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.
Study relevance score: medium
We assessed the effects of calcium treatment in a study focused on plasma exchanges for patients with atypical hemolytic uremic syndrome (aHUS). While the research primarily investigated the safety and efficacy of a plasma exchange, calcium was used during the procedure to prevent complications.
Interestingly, we found that administering intravenous calcium gluconate was associated with a lower incidence of certain adverse events during plasma exchange. However, the specific impact on hives or skin reactions was not directly analyzed within the study.
Overall, the findings suggest that while calcium treatment shows some protective effects during plasma exchanges, it did not provide conclusive evidence about its effectiveness against hives. Thus, we cannot definitively state that calcium effectively addresses hive-related issues in this context.
Interestingly, we found that administering intravenous calcium gluconate was associated with a lower incidence of certain adverse events during plasma exchange. However, the specific impact on hives or skin reactions was not directly analyzed within the study.
Overall, the findings suggest that while calcium treatment shows some protective effects during plasma exchanges, it did not provide conclusive evidence about its effectiveness against hives. Thus, we cannot definitively state that calcium effectively addresses hive-related issues in this context.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.3
6
No allergic reactions
This is by far my favourite whey protein and the only one I can consume without severe allergies. The taste is just as described and does not resemble chalk! It’s delicious! I’ve tried vanilla ice cream and Double Rich Chocolate flavours, both are scrumptious. Previously, I’ve had life-threatening allergic reactions from other brands leading to hives and breathing difficulties, but this product has been fine for the last 3 months. I’ve included it in my daily smoothie, and it tastes delightful!
Read More
